Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020091036 - EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION

Publication Number WO/2020/091036
Publication Date 07.05.2020
International Application No. PCT/JP2019/043013
International Filing Date 01.11.2019
IPC
A61K 31/4152 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4151,2-Diazoles
4152having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 9/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
A61K 47/32 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/36 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/38 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
38Cellulose; Derivatives thereof
A61P 21/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
21Drugs for disorders of the muscular or neuromuscular system
02Muscle relaxants, e.g. for tetanus or cramps
Applicants
  • 田辺三菱製薬株式会社 MITSUBISHI TANABE PHARMA CORPORATION [JP]/[JP]
Inventors
  • 羽山 哲夫 HAYAMA, Tetsuo
  • 高橋 朋弘 TAKAHASHI, Tomohiro
  • 大村 朋幸 OMURA, Tomoyuki
  • 林 昂司 HAYASHI, Kouji
  • 松田 宗智 MATSUDA, Munetomo
  • 宮澤 忠 MIYAZAWA, Tadashi
Agents
  • 山尾 憲人 YAMAO, Norihito
  • 新田 昌宏 NITTA, Masahiro
Priority Data
2018-20764602.11.2018JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION
(FR) SUSPENSION D'ÉDARAVONE DESTINÉE À ÊTRE ADMINISTRÉE PAR VOIE ORALE
(JA) 経口投与用エダラボン懸濁剤
Abstract
(EN)
Provided is an edaravone suspension for oral administration that has excellent bioavailability. It is expected that burden on ALS patients and care workers can be reduced thereby.
(FR)
L'invention concerne une suspension d'édaravone destinée à être administrée par voie orale qui présente une excellente biodisponibilité. On suppose que la charge sur les patients atteints de SLA et sur les personnels de soins de santé peut ainsi être réduite.
(JA)
本発明によれば、優れたバイオアベイラビリティを有する経口投与用のエダラボン懸濁剤が提供され、ALS患者や介護者の負担を軽減することが期待できる。
Latest bibliographic data on file with the International Bureau